Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-09-25 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
国浩律师（南京）事务所关于江苏德源药业股份有限公司2025年第一次临时股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 81% confidence The document is a law firm’s legal opinion letter on the first 2025 extraordinary shareholders’ meeting of Jiangsu Deyuan Pharmaceutical Co., Ltd. It reviews the convening procedures, attendee qualifications, voting procedures, and then details the official vote counts for each resolution. Under our taxonomy, a document providing official results of shareholder votes at a general meeting falls under Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-09-25 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled "江苏德源药业股份有限公司章程" which translates to "Articles of Association of Jiangsu Deyuan Pharmaceutical Co., Ltd." It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and other governance-related topics. The content includes company bylaws, shareholder meeting procedures, board responsibilities, and regulatory compliance references. There is no indication that this is an annual report, financial statement, or any other type of financial disclosure. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, supporting a high confidence in this classification.
2025-09-25 Chinese
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder voting outcomes and governance changes such as the cancellation of the supervisory board and amendments to company bylaws. There are no financial statements or earnings data, nor is this a presentation or a report publication announcement. The document fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from a shareholders meeting.
2025-09-25 Chinese
持股5%以上股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and timing of the reduction, compliance with relevant laws, and risk warnings. This type of document is a notification about a major shareholder's intention to sell shares, which fits the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, nor is it an announcement of a report publication. It is a regulatory announcement about shareholding changes by a significant shareholder.
2025-09-22 Chinese
独立董事工作制度
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the internal governance rules, duties, nomination, election, and responsibilities of independent directors within the company. It references relevant laws, regulatory bodies such as the China Securities Regulatory Commission (中国证监会), and the Beijing Stock Exchange rules. The document is a comprehensive internal governance policy rather than a financial report, earnings release, or announcement of voting results. It is not a report publication announcement since it contains substantive content and is not merely announcing a report. It is not a management change announcement or a legal proceeding update. The content fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to independent directors.
2025-09-09 Chinese
股东会累积投票制实施细则
Governance Information Classification · 95% confidence The document is titled '股东会累积投票制实施细则' which translates to 'Implementation Rules for Cumulative Voting System at Shareholders' Meeting'. It details the procedures, rules, and regulations regarding the cumulative voting system for electing directors at the shareholders' meeting. It includes sections on nomination, voting, and election of directors, and references company bylaws and relevant laws. The document is a formal announcement of internal governance rules related to shareholder voting procedures rather than a report of financial results, management changes, or meeting materials. It is not a report of voting results but a procedural rule document. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2790 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2025-09-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.